

Hydroxyurea (hydroxycarbamide) for sickle cell disease

The Cochrane Library

2017, CD002202

DOI: [10.1002/14651858.cd002202.pub2](https://doi.org/10.1002/14651858.cd002202.pub2)

Citation Report

#	ARTICLE	IF	CITATIONS
1	Effects of Hydroxyurea Exposure on the Rat Cerebellar Neuroepithelium: an Immunohistochemical and Electron Microscopic Study Along the Anteroposterior and Mediolateral Axes. <i>Neurotoxicity Research</i> , 2017, 32, 671-682.	1.3	6
2	Pharmacotherapeutical strategies in the prevention of acute, vaso-occlusive pain in sickle cell disease: a systematic review. <i>Blood Advances</i> , 2017, 1, 1598-1616.	2.5	34
3	Phytomedicines (medicines derived from plants) for sickle cell disease. <i>The Cochrane Library</i> , 2018, 2, CD004448.	1.5	6
4	Hydroxyurea (hydroxycarbamide) genotoxicity in pediatric patients with sickle cell disease. <i>Pediatric Blood and Cancer</i> , 2018, 65, e27022.	0.8	9
5	Improving routine outpatient monitoring for patients with sickle-cell disease on hydroxyurea. <i>BMJ Open Quality</i> , 2018, 7, e000218.	0.4	2
6	Sickle cell crisis: A crisis of a different sort?. <i>Archives of Disease in Childhood: Education and Practice Edition</i> , 2018, 103, edpract-2017-313899.	0.3	1
7	Endothelin type A receptors mediate pain in a mouse model of sickle cell disease. <i>Haematologica</i> , 2018, 103, 1124-1135.	1.7	25
8	Sickle cell disease: a malady beyond a hemoglobin defect in cerebrovascular disease. <i>Expert Review of Hematology</i> , 2018, 11, 45-55.	1.0	15
9	Association between Participants' Characteristics, Patient-Reported Outcomes, and Clinical Outcomes in Youth with Sickle Cell Disease. <i>BioMed Research International</i> , 2018, 2018, 1-8.	0.9	29
10	TRIAMF: A New Method for Delivery of Cas9 Ribonucleoprotein Complex to Human Hematopoietic Stem Cells. <i>Scientific Reports</i> , 2018, 8, 16304.	1.6	36
11	Metal Antagonists and Metals. <i>Side Effects of Drugs Annual</i> , 2018, 40, 279-288.	0.6	3
12	Targeted Hydroxyurea Education after an Emergency Department Visit Increases Hydroxyurea Use in Children with Sickle Cell Anemia. <i>Journal of Pediatrics</i> , 2018, 201, 221-228.e16.	0.9	12
13	Treatment patterns and economic burden of sickle-cell disease patients prescribed hydroxyurea: a retrospective claims-based study. <i>Health and Quality of Life Outcomes</i> , 2019, 17, 155.	1.0	40
14	Effect of N(Epsilon)-(carboxymethyl)lysine on Laboratory Parameters and Its Association with β 2SHaplotypes in Children with Sickle Cell Anemia. <i>Disease Markers</i> , 2019, 2019, 1-8.	0.6	2
15	cGMP modulation therapeutics for sickle cell disease. <i>Experimental Biology and Medicine</i> , 2019, 244, 132-146.	1.1	21
17	Association between clinical outcomes and metformin use in adults with sickle cell disease and diabetes mellitus. <i>Blood Advances</i> , 2019, 3, 3297-3306.	2.5	9
18	Interventions for treating neuropathic pain in people with sickle cell disease. <i>The Cochrane Library</i> , 2019, 7, CD012943.	1.5	6
19	Phytomedicines (medicines derived from plants) for sickle cell disease. <i>The Cochrane Library</i> , 2020, 9, CD004448.	1.5	2

#	ARTICLE	IF	CITATIONS
20	Polymorphisms in Inflammatory Genes Modulate Clinical Complications in Patients With Sickle Cell Disease. <i>Frontiers in Immunology</i> , 2020, 11, 2041.	2.2	10
21	Current and novel therapies for the prevention of vaso-occlusive crisis in sickle cell disease. <i>Therapeutic Advances in Hematology</i> , 2020, 11, 204062072095500.	1.1	22
22	Hydroxyurea treatment is associated with reduced degree of oxidative perturbation in children and adolescents with sickle cell anemia. <i>Scientific Reports</i> , 2020, 10, 18982.	1.6	5
23	Crizanlizumab and comparators for adults with sickle cell disease: a systematic review and network meta-analysis. <i>BMJ Open</i> , 2020, 10, e034147.	0.8	7
24	Association of HIV infection with clinical and laboratory characteristics of sickle cell disease. <i>BMC Infectious Diseases</i> , 2020, 20, 638.	1.3	4
25	Foetal haemoglobin inducers for reducing blood transfusion in non-transfusion dependent beta thalassaemias. <i>The Cochrane Library</i> , 0, , .	1.5	0
26	Patient-reported outcomes in sickle cell disease and association with clinical and psychosocial factors: Report from the sickle cell disease implementation consortium. <i>American Journal of Hematology</i> , 2020, 95, 1066-1074.	2.0	24
27	Recent Advances in the Treatment of Sickle Cell Disease. <i>Frontiers in Physiology</i> , 2020, 11, 435.	1.3	114
28	Hematopoietic stem cell transplantation for people with sickle cell disease. <i>The Cochrane Library</i> , 2020, 2020, CD007001.	1.5	2
29	Priorities for Improving Outcomes for Nonmalignant Blood Diseases: A Report from the Blood and Marrow Transplant Clinical Trials Network. <i>Biology of Blood and Marrow Transplantation</i> , 2020, 26, e94-e100.	2.0	3
30	Educational needs of patients and caregivers living with sickle cell disease results in development of web-based patient decision aid. <i>Journal of Advanced Nursing</i> , 2021, 77, 1432-1441.	1.5	1
31	A systematic review of quality of life in sickle cell disease and thalassemia after stem cell transplant or gene therapy. <i>Blood Advances</i> , 2021, 5, 570-583.	2.5	38
32	Sickle Cell Retinopathy. , 2021, , 1-21.		0
33	PERFIL DE MULHERES COM ÃSCLERAS DA PERNA DECORRENTES DE DOENÃA FALCIFORME. <i>ESTIMA Brazilian Journal of Enterostomal Therapy</i> , 0, , .	0.1	0
35	PROFILE OF WOMEN WITH LEG ULCERS DUE TO SICKLE CELL DISEASE. <i>ESTIMA Brazilian Journal of Enterostomal Therapy</i> , 0, , .	0.1	1
36	Thrombocytosis in children and adolescentsâ classification, diagnostic approach, and clinical management. <i>Annals of Hematology</i> , 2021, 100, 1647-1665.	0.8	10
37	A comprehensive review of hydroxyurea for Î²-haemoglobinopathies: the role revisited during COVID-19 pandemic. <i>Orphanet Journal of Rare Diseases</i> , 2021, 16, 114.	1.2	23
38	Engaging Caregivers and Providers of Children With Sickle Cell Anemia in Shared Decision Making for Hydroxyurea: Protocol for a Multicenter Randomized Controlled Trial. <i>JMIR Research Protocols</i> , 2021, 10, e27650.	0.5	8

#	ARTICLE	IF	CITATIONS
39	Cost-effectiveness of a hypothetical cell or gene therapy cure for sickle cell disease. Scientific Reports, 2021, 11, 10838.	1.6	15
40	Innovative Treatments for Rare Anemias. HemaSphere, 2021, 5, e576.	1.2	13
41	Time to rethink haemoglobin threshold guidelines in sickle cell disease. British Journal of Haematology, 2021, 195, 518-522.	1.2	7
42	Hydroxyurea—The Good, the Bad and the Ugly. Genes, 2021, 12, 1096.	1.0	49
43	Pediatric Stroke: Overview and Recent Updates. , 2021, 12, 1043.		20
44	Efficacy and safety of oral hydroxyurea in transfusion-dependent β^2 -thalassaemia: a protocol for randomised double-blind controlled clinical trial. BMJ Open, 2020, 10, e041958.	0.8	8
45	The Hazards of Hazardous Drug Labeling: Time to Revisit Hydroxyurea?. , 2019, 16, .		2
46	Fibrotic Lung Toxicity Induced by Hydroxycarbamide. In Vivo, 2017, 31, 1221-1223.	0.6	3
47	Antisickling Effects of Quercetin may be Associated with Modulation of Deoxyhaemoglobin, 2, 3-bisphosphoglycerate mutase, Redox Homeostasis and Alteration of Functional Chemistry in Human Sickle Erythrocytes.. Annals of Science and Technology, 2019, 4, 38-47.	0.2	5
48	Evaluation of hydroxyurea genotoxicity in patients with sickle cell disease. Einstein (Sao Paulo,) Tj ETQq1 1 0.784314.rgBT /Overlock 10 0,3 6		
49	Hydroxyurea: Pattern of Use, Patient Adherence, and Safety Profile in Patients with Sickle Cell Disease in Oman. Oman Medical Journal, 2019, 34, 327-335.	0.3	12
50	Homozygous sickle cell disease related mortality in Senegal (2011–2020). EJHaem, 2021, 2, 711-715.	0.4	2
51	Interventions for treating neuropathic pain in people with sickle cell disease. The Cochrane Library, 0, , .	1.5	5
52	Improving Preventive Care for Children With Sickle Cell Anemia: A Quality Improvement Initiative. Pediatric Quality & Safety, 2021, 6, e379.	0.4	3
54	Sickle Cell Retinopathy. , 2020, , 1-21.		0
55	Testicular infarction in a patient with sickle cell anemia: A case report. International Journal of Health Sciences, 2018, 12, 100-102.	0.4	1
56	The Use of Hydroxyurea in the Treatment of COVID-19. The Journal of Critical Care Medicine, 2021, 7, 312-317.	0.3	4
57	A randomised double-blind placebo-controlled clinical trial of oral hydroxyurea for transfusion-dependent β^2 -thalassaemia. Scientific Reports, 2022, 12, 2752.	1.6	14

#	ARTICLE	IF	CITATIONS
58	Higher hydroxyurea adherence among young adults with sickle cell disease compared to children and adolescents. <i>Annals of Medicine</i> , 2022, 54, 683-693.	1.5	4
59	Testicular Tissue Banking for Fertility Preservation in Young Boys: Which Patients Should Be Included?. <i>Frontiers in Endocrinology</i> , 2022, 13, 854186.	1.5	15
60	Treatment of sickle cell disease: Beyond hydroxyurea. , 0, .		0
61	Life-Threatening Acute Chest Syndrome in a Patient With Sickle Cell Disease After Switching From Hydroxyurea Therapy to Partial Exchange Transfusions: A Case Report. <i>Cureus</i> , 2021, 13, e20236.	0.2	0
62	Patientâ€focused inquiry on hydroxyurea therapy adherence and reasons for discontinuation in adults with sickle cell disease. <i>American Journal of Hematology</i> , 2022, 97, .	2.0	4
69	Sickle Cell Retinopathy. , 2022, , 3103-3123.		0
70	Accuracy of online medical information: the case of social media in sickle cell disease. <i>Pediatric Hematology and Oncology</i> , 2023, 40, 99-107.	0.3	3
71	Sickle Cell Disease, a Review. <i>Hemato</i> , 2022, 3, 341-366.	0.2	9
72	Recent advances in â€sickle and nicheâ€research - Tribute to Dr. Paul S Frenette -. <i>Stem Cell Reports</i> , 2022, 17, 1509-1535.	2.3	8
73	Health-Related Quality of Life and Adherence to Hydroxyurea and Other Disease-Modifying Therapies among Individuals with Sickle Cell Disease: A Systematic Review. <i>BioMed Research International</i> , 2022, 2022, 1-8.	0.9	6
75	Effective therapies for sickle cell disease: are we there yet?. <i>Trends in Genetics</i> , 2022, , .	2.9	3
76	Prevalence of people with sickle cell disease and leg ulcers in Brazil: Socioeconomic and clinical overview. <i>PLoS ONE</i> , 2022, 17, e0274254.	1.1	1
77	Exercise Capacity and Biomarkers Among Children and Adolescents With Sickle Cell Disease. <i>Pediatric Exercise Science</i> , 2023, 35, 84-91.	0.5	1
78	Hydroxyurea (hydroxycarbamide) for sickle cell disease. <i>The Cochrane Library</i> , 2022, 2022, .	1.5	11
79	Sickle Cell Disease in Children and Adolescents: A Review of the Historical, Clinical, and Public Health Perspective of Sub-Saharan Africa and Beyond. <i>International Journal of Pediatrics (United Kingdom)</i> , 2022, 2022, 1-26.	0.2	9
80	Incidence of cancer and related deaths in hemoglobinopathies: A followâ€up of 4631 patients between 1970 and 2021. <i>Cancer</i> , 2023, 129, 107-117.	2.0	7
81	Utilization of Hydroxyurea Among Patients Diagnosed with Sickle Cell Disease in Jazan, Saudi Arabia. <i>Patient Preference and Adherence</i> , 0, Volume 16, 3059-3067.	0.8	1
82	The impact of Hydroxyurea on the rates of Vasoâ€occlusive crises in patients with sickle cell disease in Saudi Arabia: a singleâ€center study. <i>BMC Emergency Medicine</i> , 2022, 22, .	0.7	1

#	ARTICLE	IF	CITATIONS
85	Transcranial Doppler Ultrasonography-Related Research in the Caribbean Region. <i>Cureus</i> , 2023, , .	0.2	0
86	Allogeneic hematopoietic stem cell transplantation to cure sickle cell disease: A review. <i>Frontiers in Medicine</i> , 0, 10, .	1.2	7
87	Heteroatom (B, N, P, and S)-Doped Cyclodextrin as a Hydroxyurea (HU) Drug Nanocarrier: A Computational Approach. <i>ACS Omega</i> , 2023, 8, 9861-9872.	1.6	14